Recent advances in systemic therapy have significantly enhanced survival outcomes for patients with metastatic breast cancer. Treatment selection is now primarily guided by tumor biology, including hormone-receptor and HER2-status, as delineated by contemporary NCCN guidelines. This paradigm underscores the shift towards biomarker-driven, personalized therapeutic strategies, which optimize efficacy and improve prognoses in the modern management of advanced disease.